ArticleCentral-European journal of immunology2026
Uncovering common pathways and potential drug targets in COVID-19 and venous thrombosis
Article in Central-European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: COVID-19 and venous thrombosis pose significant global health challenges. Recent studies suggest a potential overlap in their underlying molecular mechanisms, particularly immune responses and inflammation. This study aims to elucidate shared molecular pathways between COVID-19 and venous thrombosis, identify common biomarkers, and propose potential therapeutic targets through a comprehensive multi-dataset analysis. Material and methods: Public datasets (GSE171110, GSE189990, GSE178246, GSE48000, and GSE19151) were analyzed using the "Limma" package in R for differential gene expression analysis. Functional enrichment (GO, KEGG) was conducted via the "ClusterProfiler" package. Protein-protein interaction (PPI) networks, transcription factor (TF)-target, and miRNA-target networks were constructed using TRRUST and miRDB databases. Drug sensitivity was assessed using CellMiner, and feature genes were identified using LASSO regression. Immune infiltration analysis was performed with CIBERSORT, and key genes were validated using qRT-PCR and animal models. Results: Key differentially expressed genes (DEGs), including SELP and CLEC4D, were identified, highlighting their roles in immune regulation and thrombosis. Drug sensitivity analysis revealed correlations with specific chemotherapeutic agents. Immune infiltration analysis demonstrated increased expression of SELP and CLEC4D in certain immune cells, confirmed by qRT-PCR and in animal models. Conclusions: This study uncovered shared molecular mechanisms between COVID-19 and venous thrombosis, identifying potential biomarkers and therapeutic targets such as SELP and CLEC4D. These findings provide new insights into the diagnosis and treatment of both conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.